Reimbursement Scheme Forxiga® (dapagliflozin) 10 mg for patients with diabetes partially stopped
From September 1st 2021 onwards, Forxiga® (dapagliflozin) 10 mg for the treatment of adults with type 2 diabetes mellitus with a very high risk of cardiovascular disease is fully reimbursed by the health insurer.
With this reimbursement, the Reimbursement Solution of Forxiga® (dapagliflozin) 10 mg for patients with diabetes and a very high risk of cardiovascular disease will expire on 1 September 2021. For patients who do NOT fall under these new reimbursement conditions, a decision will be made in 6 months on the continuation and implementation of the current TBR and the current TBR will continue to apply.
Very high risk means:
• previously proven cardiovascular disease; and/or
• chronic kidney disease with
− eGFR 30-59 ml/min per 1.73m2 with moderately elevated albuminuria (ACR > 3 mg/mmol/l); or
− eGFR ≥ 60 ml/min per 1.73 m2 with severely elevated albuminuria (ACR > 30 mg/mmol)
Declarations of Forxiga® (dapagliflozin) 10 mg for patients with diabetes and a very high risk of cardiovascular disease, with an issue date between July 1st 2019 and September 1st, 2021, can still be submitted to TBR Nederland until December 31, 2021.
Pharmacists can declare the payment digitally. Patients can claim digitally or by post.
Who can submit a claim
Patients or their caregivers can claim the Personal Contribution Forxiga® (dapagliflozine) 10 mg online or by post. Online will be the fastest option. Pharmacists can also claim this medicine on behalf of the patient. This can only be submitted online.
NL-7744 EXP 31/08/22